Get the Stockscreener App
152.48
3.61%
5.31
After Hours:
152.49
0.01
+0.01%
Illumina Inc stock is traded at $152.48, with a volume of 2.27M.
It is up +3.61% in the last 24 hours and up +13.13% over the past month.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
See More
Previous Close:
$147.17
Open:
$147.27
24h Volume:
2.27M
Relative Volume:
1.28
Market Cap:
$23.30B
Revenue:
$4.28B
Net Income/Loss:
$1.26B
P/E Ratio:
19.31
EPS:
7.8957
Net Cash Flow:
$943.00M
1W Performance:
+5.91%
1M Performance:
+13.13%
6M Performance:
+60.85%
1Y Performance:
+7.90%
1-Day Range:
$147.27
$153.11
1-Week Range:
$137.00
$153.11
52-Week Range:
$68.70
$153.11
Illumina Inc Stock (ILMN) Company Profile
Name
Illumina Inc
Sector
Industry
Phone
(858) 202-4500
Address
5200 ILLUMINA WAY, SAN DIEGO, CA
Compare ILMN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ILMN
Illumina Inc
|
152.48 | 22.49B | 4.28B | 1.26B | 943.00M | 7.8957 |
|
TMO
Thermo Fisher Scientific Inc
|
636.30 | 232.57B | 43.74B | 6.58B | 6.11B | 17.31 |
|
DHR
Danaher Corp
|
242.05 | 165.52B | 24.27B | 3.50B | 5.02B | 4.8589 |
|
IDXX
Idexx Laboratories Inc
|
696.46 | 54.78B | 4.17B | 1.03B | 940.22M | 12.61 |
|
IQV
Iqvia Holdings Inc
|
241.40 | 39.80B | 15.90B | 1.28B | 2.21B | 7.2842 |
|
A
Agilent Technologies Inc
|
139.77 | 38.51B | 6.95B | 1.30B | 1.15B | 4.5696 |
Illumina Inc Stock (ILMN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-12-25 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Jul-11-25 | Downgrade | Scotiabank | Sector Outperform → Sector Perform |
| Mar-04-25 | Reiterated | Citigroup | Neutral |
| Feb-28-25 | Downgrade | HSBC Securities | Buy → Hold |
| Feb-10-25 | Downgrade | Barclays | Equal Weight → Underweight |
| Feb-07-25 | Downgrade | TD Cowen | Buy → Hold |
| Dec-11-24 | Downgrade | Citigroup | Buy → Neutral |
| Nov-12-24 | Resumed | Morgan Stanley | Equal-Weight |
| Oct-17-24 | Upgrade | HSBC Securities | Hold → Buy |
| Aug-28-24 | Upgrade | Argus | Hold → Buy |
| Aug-16-24 | Upgrade | Daiwa Securities | Neutral → Buy |
| Aug-14-24 | Upgrade | Barclays | Underweight → Equal Weight |
| Aug-14-24 | Upgrade | TD Cowen | Hold → Buy |
| Jul-10-24 | Upgrade | Citigroup | Neutral → Buy |
| Jun-03-24 | Resumed | Jefferies | Hold |
| Jan-16-24 | Downgrade | HSBC Securities | Buy → Hold |
| Jan-04-24 | Downgrade | TD Cowen | Outperform → Market Perform |
| Dec-18-23 | Upgrade | Scotiabank | Sector Perform → Sector Outperform |
| Dec-15-23 | Upgrade | Bernstein | Underperform → Mkt Perform |
| Dec-14-23 | Initiated | Guggenheim | Buy |
| Dec-14-23 | Initiated | Stephens | Overweight |
| Dec-13-23 | Initiated | Wolfe Research | Outperform |
| Dec-12-23 | Downgrade | BofA Securities | Neutral → Underperform |
| Dec-11-23 | Upgrade | Citigroup | Sell → Neutral |
| Nov-10-23 | Downgrade | Canaccord Genuity | Buy → Hold |
| Sep-28-23 | Initiated | Bernstein | Underperform |
| Jul-05-23 | Resumed | JP Morgan | Neutral |
| Jan-25-23 | Downgrade | Argus | Buy → Hold |
| Jan-05-23 | Initiated | Scotiabank | Sector Perform |
| Dec-12-22 | Downgrade | Citigroup | Neutral → Sell |
| Dec-07-22 | Initiated | RBC Capital Mkts | Outperform |
| Oct-04-22 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Sep-28-22 | Upgrade | Evercore ISI | In-line → Outperform |
| Aug-25-22 | Initiated | Credit Suisse | Neutral |
| Jul-13-22 | Downgrade | Barclays | Equal Weight → Underweight |
| Jan-18-22 | Upgrade | Stifel | Hold → Buy |
| Jan-11-22 | Upgrade | Barclays | Underweight → Equal Weight |
| Jan-07-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Jan-06-22 | Resumed | Morgan Stanley | Equal-Weight |
| Jan-06-22 | Resumed | Piper Sandler | Overweight |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Aug-19-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Jun-01-21 | Upgrade | Evercore ISI | Underperform → In-line |
| Mar-31-21 | Downgrade | Atlantic Equities | Overweight → Neutral |
| Mar-31-21 | Upgrade | Canaccord Genuity | Hold → Buy |
| Mar-03-21 | Initiated | Barclays | Underweight |
| Dec-22-20 | Upgrade | Piper Sandler | Neutral → Overweight |
| Dec-17-20 | Upgrade | BTIG Research | Neutral → Buy |
| Oct-13-20 | Downgrade | Guggenheim | Buy → Neutral |
| Sep-30-20 | Initiated | Atlantic Equities | Overweight |
| Sep-29-20 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Sep-22-20 | Downgrade | Stifel | Buy → Hold |
| Sep-22-20 | Downgrade | UBS | Buy → Neutral |
| Sep-21-20 | Upgrade | Guggenheim | Neutral → Buy |
| Sep-21-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Sep-09-20 | Initiated | Morgan Stanley | Equal-Weight |
| Aug-07-20 | Downgrade | Evercore ISI | In-line → Underperform |
| Aug-07-20 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jul-07-20 | Downgrade | Guggenheim | Buy → Neutral |
| Apr-24-20 | Downgrade | Citigroup | Buy → Neutral |
| Apr-21-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jan-08-20 | Initiated | Wells Fargo | Underweight |
| Jan-07-20 | Initiated | Citigroup | Buy |
| Jan-02-20 | Downgrade | Evercore ISI | Outperform → In-line |
| Nov-15-19 | Initiated | Stifel | Buy |
| Oct-25-19 | Initiated | Guggenheim | Buy |
View All
Illumina Inc Stock (ILMN) Latest News
Next Generation Sequencing Market Size to Worth USD 103.24 Bn by 2035 - GlobeNewswire Inc.
The Truth About Illumina Inc.: Is This Genomics Giant Still Worth Your Money? - AD HOC NEWS
Illumina (NASDAQ:ILMN) Sets New 52-Week HighHere's What Happened - MarketBeat
Illumina and Powell Gilbert in love with Lisbon - JUVE Patent
Illumina stock hits 52-week high at 151.35 USD - Investing.com
What Does Illumina Do? Insights on NGS Technologies - www.whatjobs.com
North America Bioinformatics Market Size, Share, Trends, - openPR.com
Illumina Secures CMS Reimbursement for TruSight Oncology Test at $2,989.55 - Intellectia AI
Illumina Gets Medicare Boost for Cancer Test, Shares Climb - Benzinga
Customer Engagement Center - Illumina
Illumina secures CMS reimbursement for cancer genomic test at $2,989 - Investing.com
Illumina Gets Reimbursement For FDA-Approved TruSight Oncology Comprehensive Test, Stock Down - Nasdaq
Press Release - Illumina
Medicare to cover $2,989.55 Illumina genomic cancer test - Stock Titan
Stifel raises Illumina stock price target to $155 on growth outlook - Investing.com
GRAIL Inc.Illumina's Divested Holy Grail (NASDAQ:GRAL) - Seeking Alpha
Illumina Inc. (ILMN) Shares See Target Boost as Analysts See Potential 2026 Upside - Insider Monkey
The Technical Signals Behind (ILMN) That Institutions Follow - Stock Traders Daily
Illumina: What Is Next In This Sequence? (NASDAQ:ILMN) - Seeking Alpha
The Bull Case For Illumina (ILMN) Could Change Following Its Billion Cell Atlas Pharma Alliance - Yahoo Finance
2MM: AI Roundup – Lilly and NVIDIA’s $1B AI lab, Illumina’s Billion Cell Atlas, AstraZeneca’s Modella deal, and Claude for Healthcare [Jan 19th, 2026] - 2 Minute Medicine
Is Now An Opportune Moment To Examine Illumina, Inc. (NASDAQ:ILMN)? - 富途资讯
Nordea Investment Management AB Buys 19,519 Shares of Illumina, Inc. $ILMN - MarketBeat
Oncology Research Solutions - Illumina
Stephens Investment Management Group LLC Boosts Holdings in Illumina, Inc. $ILMN - MarketBeat
Illumina, Inc. $ILMN Shares Acquired by ASR Vermogensbeheer N.V. - MarketBeat
Illumina Inc. Stock Underperforms Friday When Compared To Competitors - 富途资讯
Illumina, Inc.Common Stock (NQ: ILMN - FinancialContent
Illumina partners with pharma giants to map disease biology at unprecedented scale - Mugglehead Magazine
2026: A turning point for precision health - Illumina
Illumina reports preliminary Q4 revenue of $1.15B - MSN
Illumina's new connected multiomics platform set to boost its stock - MSN
Sumitomo Mitsui Trust Group Inc. Acquires 54,987 Shares of Illumina, Inc. $ILMN - MarketBeat
Illumina reports 5% revenue growth in Q4 2025, flat for full year - Investing.com Nigeria
Illumina launches billion cell atlas to boost AI-driven drug discovery - Investing.com Nigeria
Illumina Launches Billion Cell Atlas to Accelerate AI-Driven Drug Development - filmogaz.com
Illumina introduces Billion Cell Atlas to accelerate AI and drug discovery - The Malaysian Reserve
Illumina CEO Sees Big Growth Opportunity in China - marketscreener.com
Illumina Announces Alliance Framework with AstraZeneca, Merck, and Eli Lilly and Company - marketscreener.com
JPM26: Illumina debuts Billion Cell Atlas to drive AI-driven drug discovery - Pharmaceutical Technology
Illumina Produces Midteens Earnings Growth in 2025, Distancing Itself From the Grail Debacle - Morningstar
Canada Next-Generation Sequencing (NGS) Market Analysis and Forecast, 2025-2035, Featuring Illumina, Oxford Nanopore Technologies, Pacific Bioscience of California, MGI Tech Co., QIAGEN and More - GlobeNewswire
Illumina (NASDAQ:ILMN) Updates Q4 2025 Earnings Guidance - MarketBeat
Illumina launches massive cell atlas to fast-track drug discovery - statnews.com
Press Release: Illumina Announces Preliminary Unaudited Financial Results for Fourth Quarter and Fiscal Year 2025 - 富途牛牛
Illumina introduces Billion Cell Atlas, genome-wide genetic perturbation dataset - marketscreener.com
Illumina Billion Cell Atlas to accelerate AI, drug discovery - BioWorld MedTech
Illumina Introduces Illumina Billion Cell Atlas To Accelerate AI Drug Discovery - Nasdaq
Illumina unveils dataset to speed up AI-powered drug discovery - Reuters
Illumina introduces billion cell atlas to accelerate AI and drug discovery - marketscreener.com
Illumina Introduces Genetic Perturbation Dataset to Further AI Drug Discovery - marketscreener.com
Illumina Inc Stock (ILMN) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.35%
0.80%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):